Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction

American Journal of Cardiology

Volumn 104, Issue 10, 2009, Pages 1370-1376

  Lee, Cheol Whan ^a   Park, Duk Woo ^a   Lee, Seung Hwan ^a   Kim, Young Hak ^a   Hong, Myeong Ki ^a   Kim, Jae Joong ^a   Park, Seong Wook ^a   Yun, Sung Cheol ^a   Seong, In Whan ^c   Lee, Jae Hwan ^c   Lee, Nae Hee ^d   Cho, Yoon Haeng ^d   Cheong, Sang Sig ^e   Lim, Do Sun ^b   Yang, Joo Young ^f   Lee, Sang Gon ^g   Kim, Kee Sik ^h   Yoon, Junghan ⁱ   Jeong, Myung Ho ^j   Seung, Ki Bae ^k   Hong, Taeg Jong ^l   Park, Seung Jung ^a   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d Soonchunhyang University   (South Korea)

^e Asan Medical Center   (South Korea)

^f National Health Insurance Corporation   (South Korea)

^g Ulsan University College of Medicine   (South Korea)

^h Catholic University of Daegu   (South Korea)

ⁱ Wonju Severance Christian Hospital   (South Korea)

^j Chonnam National University Medical School   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l Pusan National University Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; STENT THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; SIROLIMUS; TICLOPIDINE;

EID: 72049099355     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.059     Document Type: Article

References (30)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
2. Zhu M.M., Feit A., Chadow H., Alam M., Kwan T., and Clark L.T. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 88 (2001) 297-301
3. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., Cutlip D.E., Fahy M., Pocock S.J., Mehran R., and Leon M.B. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
5. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabaté M., Suttorp M.J., Baumgart D., Seyfarth M., Pfisterer M.E., and Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
6. Tu J.V., Bowen J., Chiu M., Ko D.T., Austin P.C., He Y., Hopkins R., Tarride J.E., Blackhouse G., Lazzam C., Cohen E.A., and Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
7. Beohar N., Davidson C.J., Kip K.E., Goodreau L., Vlachos H.A., Meyers S.N., Benzuly K.H., Flaherty J.D., Ricciardi M.J., Bennett C.L., and Williams D.O. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
8. Grines C.L. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol 51 (2008) 615-617
9. Daemen J., Tanimoto S., García-García H.M., Kukreja N., van de Sande M., Sianos G., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries). Am J Cardiol 99 (2007) 1027-1032
10. Steg G. DES fall from GRACE in STEMI: patients face more than fourfold higher risk of death than bare-metal stent treated patients. Heart-wire. http://www.medscape.com Accessed September 4, 2007
11. Laarman G.J., Suttorp M.J., Dirksen M.T., van Heerebeek L., Kiemeneij F., Slagboom T., van der Wieken L.R., Tijssen J.G.P., Rensing B.J., and Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
12. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrie D., Slama M.S., Merkely B., Erglis A., Margheri M., Varenne O., Cebrian A., Stoll H.P., Snead D.B., Bode C., and TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
13. Menichelli M., Parma A., Pucci E., Fiorilli R., De Felice F., Nazzaro M., Giulivi A., Alborino D., Azzellino A., and Violini R. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 49 (2007) 1924-1930
14. Valgimigli M., Percoco G., Malagutti P., Campo G., Ferrari F., Barbieri D., Cicchitelli G., McFadden E.P., Merlini F., Ansani L., Guardigli G., Bettini A., Parrinello G., Boersma E., and Ferrari R. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
15. Valgimigli M., Campo G., Percoco G., Bolognese L., Vassanelli C., Colangelo S., de Cesare N., Rodriguez A.E., Ferrario M., Moreno R., Piva T., Sheiban I., Pasquetto G., Prati F., Nazzaro M.S., Parrinello G., and Ferrari R. Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299 (2008) 1788-1799
16. Hannan E.L., Racz M., Walford G., Holmes D.R., Jones R.H., Sharma S., Katz S., and King III S.B. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 1 (2008) 129-135
17. Pasceri V., Patti G., Speciale G., Pristipino C., Richichi G., and Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754
18. Kastrati A., Dibra A., Spaulding C., Laarman G.J., Menichelli M., Valgimigli M., Lorenzo E.D., Kaiser C., Tierala I., Mehilli J., Seyfarth M., Varenne O., Dirksen M.T., Percoco G., Varricchio A., Pittl U., Syvänne M., Suttorp M.J., Violini R., and Schömig A. Meta-analysis of randomized trials on drug-eluting stents versus bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
19. Percoco G., Manari A., Guastaroba P., Campo G., Guiducci V., Aurier E., Sangiorgio P., Passerini F., Geraci G., Piovaccari G., Naldi M., Saia F., and Marzocchi A. Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry. Cardiovasc Drugs Ther 20 (2006) 63-68
20. Mauri L., Silbaugh T.S., Garg P., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Normand S.L.T. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342
21. Shishehbor M.H., Amini R., Oliveria L.P.J., Singh I.M., Kelly P., Bhatt D.L., Kapadia S.R., Ellis S.G., Whitlow P.L., and Brener S.J. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 1 (2008) 227-232
22. Kandzari D.E., and Leon M.B. Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent. J Interv Cardiol 19 (2006) 405-413
23. Gershlick A., Kandzari D.E., Leon M.B., Wijns W., Meredith I.T., Fajadet J., Popma J.J., Fitzgerald P.J., Kuntz R.E., and ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 100 suppl (2007) S45-S55
24. Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C., Ball M.W., Turco M., Applegate R.J., Gurbel P.A., Midei M.G., Badre S.S., Mauri L., Thompson K.P., LeNarz L.A., Kuntz R.E., and ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447
25. Meredith I.T., Ormiston J., Whitbourn R., Kay I.P., Muller D., Popma J.J., Cutlip D.E., Fitzgerald P.J., and ENDEAVOR I Investigators. Four-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 100 suppl 8B (2007) 56M-61M
26. Lee J.H., Kim H.S., Lee S.W., Park J.H., Choi S.W., Jeong J.O., Cho Y., Lee N., Rhee K.S., Ko J.K., and Seong I.W. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: PROSIT trial. Catheter Cardiovasc Interv 72 (2008) 25-32
27. Whelan D.M., van der Giessen W.J., Krabbendam S.C., van Vliet E.A., Verdouw P.D., Serruys P.W., and van Beusekom H.M. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 83 (2000) 338-345
28. Nakazawa G., Finn A.V., John M.C., Kolodgie F.D., and Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 100 suppl (2007) 36M-44M
29. Ellis S.G., Popma J.J., Lasala J.M., Koglin J.J., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., and Stone G.W. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1193-1200
30. Luscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., and Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058